Skip to main content
Top
Published in: Annals of Surgical Oncology 4/2018

01-04-2018 | Gastrointestinal Oncology

Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study

Authors: Adam T. Stearns, MA, DPhil, FRCS, Lee Malcomson, BSc, Grant Punnett, MSc, Haytham Abudeeb, FRCS, Omer Aziz, PhD, FRCS, Chelliah R. Selvasekar, MD, FRCS, Paul E. Fulford, FRCS, Malcolm S. Wilson, MD, FRCS, Andrew G. Renehan, PhD, FRCS, Sarah T. O’Dwyer, MD, FRCS

Published in: Annals of Surgical Oncology | Issue 4/2018

Login to get access

Abstract

Background

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are an established treatment for pseudomyxoma peritonei (PMP), but it is a major surgical procedure and may be associated with long-term morbidity. To date, health-related quality-of-life (HRQL) data among survivors are lacking.

Methods

A two-period qualitative study investigated patients undergoing CRS-HIPEC for PMP at a national peritoneal tumor center between 2003 and 2011. First, the European Organization for Research and Treatment (EORTC)-QLQ C30 HRQL questionnaire was used longitudinally preoperatively and at postoperative months 3, 6, 9, 12, 18, and 24, then yearly thereafter. Second, it was updated in 2016 as a cross-sectional study. Both studies were compared with age- and sex-matched reference populations (one-way t tests).

Results

A total of 553 longitudinal HRQL questionnaires were completed for 137 patients, truncated at 60 months. In the 2016 update, 85 responses were received from 103 survivors (mean follow-up period, 8.11 years). Patients’ physical, role, and social function scores were impaired until 12 months postoperatively, after which the scores did not differ significantly from those of with reference populations. Similarly, fatigue, appetite loss, insomnia, and financial difficulties worsened significantly compared with reference populations in the first 12-months and then normalized. In contrast, impaired cognitive function (82.3 vs 88.5; P = 0.017), constipation (13.7 vs 7.3; P = 0.032), and diarrheal symptoms (15.1 vs 4.9; P = 0.0006) persisted through both periods. Global health scores did not differ significantly from those of the reference population.

Conclusions

Beyond 12 months postoperatively, CRS-HIPEC for PMP is associated with a good quality of life except for some cognitive functional impairment and bowel disturbances.
Literature
1.
go back to reference Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol. 2016;40:14–26.CrossRefPubMed Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface oncology group international (PSOGI) modified delphi process. Am J Surg Pathol. 2016;40:14–26.CrossRefPubMed
2.
go back to reference Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.CrossRefPubMed Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.CrossRefPubMed
3.
go back to reference Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014;40:1605–13.CrossRefPubMed Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014;40:1605–13.CrossRefPubMed
4.
go back to reference Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a systematic review and meta-analysis. Surg Oncol. 2014;23:199–210.CrossRefPubMed Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a systematic review and meta-analysis. Surg Oncol. 2014;23:199–210.CrossRefPubMed
5.
go back to reference Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772–83.CrossRefPubMedPubMedCentral Dodson RM, McQuellon RP, Mogal HD, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(Suppl 5):772–83.CrossRefPubMedPubMedCentral
6.
go back to reference McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.CrossRefPubMed McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73.CrossRefPubMed
7.
go back to reference Knutsen A, Sielaff TD, Greeno E, Tuttle TM. Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg. 2006;10:1038–43.CrossRefPubMed Knutsen A, Sielaff TD, Greeno E, Tuttle TM. Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointest Surg. 2006;10:1038–43.CrossRefPubMed
8.
go back to reference Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627–32.CrossRefPubMed Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627–32.CrossRefPubMed
9.
go back to reference Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007;14:2309–18.CrossRefPubMed Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007;14:2309–18.CrossRefPubMed
10.
go back to reference Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2008;51:868–74.CrossRefPubMed Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2008;51:868–74.CrossRefPubMed
11.
go back to reference Macri A, Maugeri I, Trimarchi G, et al. Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. In Vivo. 2009;23:147–50.PubMed Macri A, Maugeri I, Trimarchi G, et al. Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. In Vivo. 2009;23:147–50.PubMed
12.
go back to reference Zenasni F, Botella M, Elias D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer. 2009;17:1255–61.CrossRefPubMed Zenasni F, Botella M, Elias D, et al. The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study. Support Care Cancer. 2009;17:1255–61.CrossRefPubMed
13.
go back to reference Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010;36:1156–61.CrossRefPubMed Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010;36:1156–61.CrossRefPubMed
14.
go back to reference Duckworth KE, McQuellon RP, Russell GB, et al. Patient-rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;106:376–80.CrossRefPubMedPubMedCentral Duckworth KE, McQuellon RP, Russell GB, et al. Patient-rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS + HIPEC). J Surg Oncol. 2012;106:376–80.CrossRefPubMedPubMedCentral
15.
go back to reference Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53–8.CrossRefPubMed Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53–8.CrossRefPubMed
16.
go back to reference Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JHT, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18:3673–9.CrossRefPubMedPubMedCentral Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JHT, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011;18:3673–9.CrossRefPubMedPubMedCentral
17.
go back to reference Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20:226–32.CrossRefPubMed Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20:226–32.CrossRefPubMed
18.
go back to reference Kirby R, Liauw W, Zhao J, Morris D. Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol. 2013;2013:461041.PubMedPubMedCentral Kirby R, Liauw W, Zhao J, Morris D. Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol. 2013;2013:461041.PubMedPubMedCentral
19.
go back to reference McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.CrossRefPubMed McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–62.CrossRefPubMed
20.
go back to reference Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.CrossRefPubMed
21.
go back to reference Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42:1035–41.CrossRefPubMed Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42:1035–41.CrossRefPubMed
22.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
23.
go back to reference Fish R, Selvasekar C, Crichton P, et al. Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. Surg Endosc. 2014;28:341–5.CrossRefPubMed Fish R, Selvasekar C, Crichton P, et al. Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. Surg Endosc. 2014;28:341–5.CrossRefPubMed
24.
go back to reference Rout S, Renehan AG, Parkinson MF, et al. Treatments and outcomes of peritoneal surface tumors through a centralized national service (United kingdom). Dis Colon Rectum. 2009;52:1705–14.CrossRefPubMed Rout S, Renehan AG, Parkinson MF, et al. Treatments and outcomes of peritoneal surface tumors through a centralized national service (United kingdom). Dis Colon Rectum. 2009;52:1705–14.CrossRefPubMed
25.
go back to reference Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36:323–9.CrossRefPubMed Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36:323–9.CrossRefPubMed
26.
go back to reference Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.CrossRefPubMed Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.CrossRefPubMed
27.
go back to reference Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer, Brussels, 2001. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer, Brussels, 2001.
28.
go back to reference Hinz A, Singer S, Brahler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014;53:958–65.CrossRefPubMed Hinz A, Singer S, Brahler E. European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol. 2014;53:958–65.CrossRefPubMed
29.
go back to reference McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:1105–13.CrossRefPubMed McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:1105–13.CrossRefPubMed
30.
go back to reference McQuellon RP, Russell GB, Shen P, Stewart JHt, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008;15:125–33.CrossRefPubMed McQuellon RP, Russell GB, Shen P, Stewart JHt, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008;15:125–33.CrossRefPubMed
31.
go back to reference Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2905–13.CrossRefPubMed Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:2905–13.CrossRefPubMed
32.
go back to reference Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. European Organisation for Research and Treatment of Cancer, Brussels, 2008. Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values. European Organisation for Research and Treatment of Cancer, Brussels, 2008.
33.
go back to reference Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ-C30 (+3). J Clin Oncol. 1998;16:1188–96.CrossRefPubMed Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ-C30 (+3). J Clin Oncol. 1998;16:1188–96.CrossRefPubMed
34.
go back to reference Schwarz R, Hinz A. Reference data for the quality-of-life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345–51.CrossRefPubMed Schwarz R, Hinz A. Reference data for the quality-of-life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37:1345–51.CrossRefPubMed
35.
go back to reference Skevington SM, Lotfy M, O’Connell KA, Group W. The World Health Organization’s WHOQOL-BREF quality-of-life assessment: psychometric properties and results of the international field trial: a report from the WHOQOL group. Qual Life Res. 2004;13:299–310.CrossRefPubMed Skevington SM, Lotfy M, O’Connell KA, Group W. The World Health Organization’s WHOQOL-BREF quality-of-life assessment: psychometric properties and results of the international field trial: a report from the WHOQOL group. Qual Life Res. 2004;13:299–310.CrossRefPubMed
36.
go back to reference Ludemann R, Watson DI, Jamieson GG. Influence of follow-up methodology and completeness on apparent clinical outcome of fundoplication. Am J Surg. 2003;186:143–7.CrossRefPubMed Ludemann R, Watson DI, Jamieson GG. Influence of follow-up methodology and completeness on apparent clinical outcome of fundoplication. Am J Surg. 2003;186:143–7.CrossRefPubMed
37.
go back to reference Nakash RA, Hutton JL, Jorstad-Stein EC, Gates S, Lamb SE. Maximising response to postal questionnaires: a systematic review of randomised trials in health research. BMC Med Res Methodol. 2006;6:5.CrossRefPubMedPubMedCentral Nakash RA, Hutton JL, Jorstad-Stein EC, Gates S, Lamb SE. Maximising response to postal questionnaires: a systematic review of randomised trials in health research. BMC Med Res Methodol. 2006;6:5.CrossRefPubMedPubMedCentral
Metadata
Title
Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study
Authors
Adam T. Stearns, MA, DPhil, FRCS
Lee Malcomson, BSc
Grant Punnett, MSc
Haytham Abudeeb, FRCS
Omer Aziz, PhD, FRCS
Chelliah R. Selvasekar, MD, FRCS
Paul E. Fulford, FRCS
Malcolm S. Wilson, MD, FRCS
Andrew G. Renehan, PhD, FRCS
Sarah T. O’Dwyer, MD, FRCS
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6326-0

Other articles of this Issue 4/2018

Annals of Surgical Oncology 4/2018 Go to the issue